NRG-GI005 |
Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA) |
Cancer |
Gastrointestinal |
NRG-GY018 |
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer |
Cancer |
Endometrial |
NRG-GY019 |
Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum https://clinicaltrials.gov/ct2/show/NCT03797326?term=NCT03797326&draw=2&rank=1 |
Cancer |
Ovarian |
NRG-HN001 |
Randomized Phase II AND Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA) |
Cancer |
Nasopharynx Carcinoma |
NRG-HN004 |
Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) Vs. Radiotherapy with Concurrent Cetuximab in Patients with Stage III-IVB Head and Neck Cancer with a Contraindication to Cisplatin |
Cancer |
Head and Neck |
NRG-HN005 |
A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients with Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer |
Cancer |
Head and Neck |
NRG-LU002 |
Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung – Cancer |
Cancer |
Lung |
NRG-LU005: Limited Stage Small Cell Lung Cancer |
A Phase II/III Randomized Study of Chemoradiation VS Chemoradiation Plus Atezolizumab |
Cancer |
Lung |
NRG-LU007 |
RAndomized Phase II/III Trial Of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR trial |
Cancer |
Lung |
NSABP FB-12: |
An Open-Label Phase II Trial to Evaluate the Efficacy and Safety of Neoadjuvant Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel Plus Trastuzumab and Pertuzumab in Early Stage HER2-Negative Breast Cancer Patients Selected with a Test Measuring Live Cell HER2 Signaling Transduction (FACT 1) |
Cancer |
Breast |
ON-TRK |
PrOspective Non-interventional study in patients with locally advanced or metastatic TRK fusion cancer treated with larotrectinib |
Cancer |
Genomic |
PFO Occulder (PAS) |
Amplatzer PFO Occluder Post Approval Study (No. SJM-CIP-10187 Ver. A) |
Heart & Vascular |
Structural Heart Disease |
Portico NG |
This is a study of an updated Portico Valve for TAVR. |
Heart & Vascular |
Structural Heart Disease |
RTOG-0724 |
Phase III Randomized Study Of Concurrent Chemotherapy and Pelvic Radiation Therapy With Or Without Adjuvant Chemotherapy In High-Risk Patients With Early-Stage Cervical Carcinoma Following Radical Hysterectomy |
Cancer |
Gynecologic |
S1608 |
Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma |
Cancer |
Hematology |
S1703 |
Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive Breast Cancer |
Cancer |
Breast |
S1706 |
A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer |
Cancer |
Breast |
S1801 |
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant MK-3475 (Pembrolizumab) for Clinically Detectable Stage III-IV High-Risk Melanoma |
Cancer |
Melanoma |
S1806 |
Phase III Randomized Trial of Concurrent Chemoradiotherapy with or without Atezolizumab in Localized Muscle Invasive Bladder Cancer |
Cancer |
Genitourinary GU |
Sync AV |
This is a new CRT with optimization turned on or off. |
Heart & Vascular |
Cardiac Arrhythmia |
The TESLA Trial |
Thrombectomy for Emergent Salvage of Large Anterior Circulation Ischemic Stroke |
Neurosciences |
Stoke |
URCC 16070 |
Netupitant/Palonosetron Hydrochloride and Dexamethasone With or Without Prochlorperazine or Olanzapine in Improving Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer |
Cancer |
Breast |
A151216 (ALCHEMIST) |
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) |
Cancer |
Lung |
Agendia FLEX |
The objective of this study is to create a large scale, population-based registry of full genome expression data and clinical data to investigate new gene associations with prognostic and/or predictive value |
Cancer |
Breast |
EA6134 |
A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma |
Cancer |
Melanoma |
EA6141 |
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma |
Cancer |
Melanoma |
EAY131 (MATCH) |
A Molecular Analysis for Therapy Choice (MATCH) - This study is a type of basket trial designed with the flexibility to open and close sub-protocols. Patients enrolled on study will have a tumor biopsy for molecular characterization and those with molecular variants addressed by treatments included in the trial will be offered treatment on MATCH. *Now using outside molecular reports which tumor must be collected within 6 months with no intervening treatment. Foundation One reports will now notify MATCH of molecular matches. |
Cancer |
Genomic testing based trial |
NRG BR003 |
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer |
Cancer |
Breast |
NRG-GU002 |
Phase II-III Trial of Adjuvant Radiotherapy Following Radical Prostatectomy With or Without Adjuvant Docetaxel |
Cancer |
Prostate |
S0820 - Prevention of High-Risk Colorectal Polyps and New Colorectal Cancers |
PACES S0820 is a study to determine the efficacy of certain drugs in the prevention of high-risk colorectal polyps and new colorectal cancers in patients with previously treated colorectal cancer. |
Cancer |
Gastro-Intestinal |